pargyline has been researched along with sk&f-38393 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abraini, JH; Fechtali, T; Rostain, JC | 1 |
| Altar, CA; Boyar, WC; Gerhardt, SC; Liebman, JM; Wasley, A; Wood, PL | 1 |
| Jenner, P; Marsden, CD | 1 |
| Benzi, M; Bertorelli, R; Consolo, S; Girotti, P; Russi, G; Zambelli, M | 1 |
| Ahlenius, S; Ericson, E; Florvall, L; Hillegaart, V; Jiménez, P; Wijkström, A | 1 |
| Alfaro-Rodriguez, A; Alonso-Spilsbury, M; Arch-Tirado, E; Avila-Luna, A; Bueno-Nava, A; Gonzalez-Pina, R | 1 |
1 review(s) available for pargyline and sk&f-38393
| Article | Year |
|---|---|
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine; Ergolines; Humans; Levodopa; Macaca mulatta; Neural Pathways; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Quinpirole; Rats; Saimiri; Selegiline; Species Specificity; Substantia Nigra | 1986 |
5 other study(ies) available for pargyline and sk&f-38393
| Article | Year |
|---|---|
Pressure reversed extracellular striatal dopamine decrease produced by D1 receptor agonist SKF 38393, and D2 receptor agonist LY 171555, but failed to change the effect of the activation of both D1 and D2 receptors.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 3,4-Dihydroxyphenylacetic Acid; alpha-Methyltyrosine; Animals; Apomorphine; Ascorbic Acid; Cerebral Ventricles; Corpus Striatum; Dopamine; Dopamine Agents; Electroencephalography; Ergolines; Homovanillic Acid; Injections, Intraventricular; Kinetics; Male; Methyltyrosines; Pargyline; Pressure; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Synapses; Uric Acid | 1992 |
Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antipsychotic Agents; Behavior, Animal; Benzazepines; Brain Chemistry; Dopamine; Dopamine Antagonists; Male; Mice; Motor Activity; Pargyline; Stereotyped Behavior | 1988 |
D1 and D2 dopamine receptors and the regulation of striatal acetylcholine release in vivo.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Acetylcholine; Animals; Benzazepines; Chromans; Corpus Striatum; Dextroamphetamine; Dopamine Agents; Dopamine Antagonists; Female; Microdialysis; Pargyline; Rats; Receptors, Dopamine; Secretory Rate | 1993 |
In vivo characterization of novel full and partial 2-(4-aminophenyl)-N,N-dipropylethylamine dopamine D(2) receptor agonists.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 4-Butyrolactone; alpha-Methyltyrosine; Animals; Brain Chemistry; Catecholamines; Dihydroxyphenylalanine; Dopamine; Dopamine Agonists; Ethylamines; Fluorobenzenes; GABA Modulators; Male; Monoamine Oxidase Inhibitors; Motor Activity; Pargyline; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Reserpine; Sympatholytics | 2000 |
The selective inhibition of the D₁ dopamine receptor results in an increase of metabolized dopamine in the rat striatum.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 3,4-Dihydroxyphenylacetic Acid; Animals; Benzazepines; Corpus Striatum; Dopamine; Dopamine Agonists; Dopamine Antagonists; Male; Pargyline; Rats; Rats, Wistar; Receptors, Dopamine D1 | 2012 |